Subtherapeutic linezolid concentrations in a patient with morbid obesity and methicillin-resistant staphylococcus aureus pneumonia: Case report and review of the literature

Annals of Pharmacotherapy

Volumn 47, Issue 6, 2013, Pages

  Muzevich, Katie M ^a   Lee, Kimberly B ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON DIOXIDE; CEFTRIAXONE; CREATININE; FUROSEMIDE; LEVOFLOXACIN; LINEZOLID; OXYGEN; VANCOMYCIN; ACETAMIDE DERIVATIVE; OXAZOLIDINONE DERIVATIVE;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTERIAL GAS; ARTICLE; BACTERIUM CULTURE; BACTERIUM DETECTION; BLOOD OXYGEN TENSION; BLOOD PH; CARBON DIOXIDE TENSION; CASE REPORT; CREATININE BLOOD LEVEL; DIASTOLIC HEART FAILURE; DIURETIC THERAPY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENDOTRACHEAL INTUBATION; FEVER; HOSPITAL ADMISSION; HUMAN; HYPOXEMIA; KIDNEY DYSFUNCTION; LEUKOCYTE COUNT; LEUKOCYTOSIS; LUNG EDEMA; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORBID OBESITY; OXYGEN TENSION; PRIORITY JOURNAL; RESPIRATORY FAILURE; SEPSIS; STAPHYLOCOCCAL PNEUMONIA; STEADY STATE; THORAX RADIOGRAPHY; TREATMENT OUTCOME; URINE VOLUME; BLOOD; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; OBESITY, MORBID; PNEUMONIA, STAPHYLOCOCCAL;

ACETAMIDES; ADULT; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OBESITY, MORBID; OXAZOLIDINONES; PNEUMONIA, STAPHYLOCOCCAL;

EID: 84893185732     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R707     Document Type: Article

References (40)

1. Package information. Zyvox (linezolid). New York, NY: Pharmacia & Upjohn Company. March 2012.
2. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52:e18-e55. doi: 10.1093/cid/ciq146
3. Ogden CL, Carroll MD, Kit BK, Flegal MD. Prevalence of obesity in the United States, 2009-2010. National Center for Health Statistics data brief, no 82, Hyattsville, MD: National Center for Health Statistics. 2012
4. Sturm R, Hattori A. Morbid obesity rates continue to rise rapidly in the United States. Int J Obes (Lond) 2012. doi: 10.1038/ijo.2012.159; 10.1038/ijo.2012.159
5. Deal EN, Hollands JM, Reichley RM, Micek ST. Characteristics of patients with morbid obesity at an academic medical center. Am J Health Syst Pharm 2010;67:1589-1590. doi: 10.2146/ajhp100086; 10.2146/ajhp100086
6. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007;27:1081-1091. doi: 10.1592/phco.27.8.1081
7. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the phar-macokinetics of drugs in humans. Clin Pharmacokinet 2010;49:71-87. doi: 10.2165/11318100-000000000-00000
8. Han PY, Duffull SB, Kirkpatrick CM, Green B. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007;82:505-508. doi: 10.1038/sj.clpt.6100381
9. Morrish GA, Pai MP, Green B. The effects of obesity on drug pharma- cokinetics in humans. Expert Opin Drug Metab Toxicol 2011;7:697-706. doi: 10.1517/17425255.2011.570331
10. Brill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet 2012;51:277-304. doi: 10.2165/11599410-000000000-00000
11. Medico CJ, Walsh P. Pharmacotherapy in the critically ill obese patient. Crit Care Clin 2010;26:679-688. doi: 10.1016/j.ccc.2010.07.003
12. Jacques KA, Erstad BL. Availability of information for dosing injectable medications in underweight or obese patients. Am J Health Syst Pharm 2010;67:1948-1950. doi: 10.2146/ajhp100226; 10.2146/ajhp100226
13. Stein GE, Schooley SL, Peloquin CA, et al. Pharmacokinetics and pharma codynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005;39:427-432. doi: 10.1345/aph.1E484
14. Mersfelder TL, Smith CL. Linezolid pharmacokinetics in an obese patient. Am J Health Syst Pharm 2005;62:464-467
15. Tsuji Y, Hiraki Y, Matsumoto K, et al. Evaluation of the pharmacokinet-ics of linezolid in an obese Japanese patient. Scand J Infect Dis 2012. doi: 10.3109/00365548.2011.652164
16. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. CLSI document M100-S22. Wayne, PA: Clinical and Laboratory Standards Institute, 2012.
17. Beringer P, Nguyen M, Hoem N, et al. Absolute bioavailability and phar-macokinetics of linezolid in hospitalized patients given enteral feedings. Antimicrob Agents Chemother 2005;49:3676-3681. doi: 10.1128/AAC.49.9.3676-3681.2005
18. Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clin ical treatment. J Antimicrob Chemother 2011;66(suppl 4):iv7-iv15. doi: 10.1093/jac/dkr072
19. Marston BJ, Plouffe JF, File TM Jr, et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997;157:1709-1718.
20. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Prevalence of methicillin-resistant Staphylococcus aureus as an etiology of community-acquired pneumonia. Clin Infect Dis 2012;54:1126-1133. doi: 10.1093/cid/cis022; 10.1093/cid/cis022
21. Lobo LJ, Reed KD, Wunderink RG. Expanded clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus pneumonia. Chest 2010;138:130-136. doi: 10.1378/chest.09-1562; 10.1378/chest.09-1562
22. Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 2008; 52:24-36. doi: 10.1128/AAC.00133-06
23. Chiu LM, Amsden GW. Intrapulmonary pharmacokinetics of antibacterial agents: implications for therapeutics. Am J Respir Med 2002;1:201-209.
24. Rello J, Mallol J. Optimal therapy for methicillin-resistant Staphylococcus aureus pneumonia: what is the best dosing regimen? Chest 2006; 130:938-940. doi: 10.1378/chest.130.4.938
25. Conte JE Jr, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharma-cokinetics of linezolid. Antimicrob Agents Chemother 2002;46:1475-1480.
26. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004;30:388-394. doi: 10.1007/s00134-003-2088-1
27. Stein GE, Wells EM. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Curr Med Res Opin 2010;26:571-588. doi: 10.1185/03007990903512057
28. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methi-cillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012;54:621-629. doi: 10.1093/cid/cir895; 10.1093/cid/cir895
29. Brickner SJ, Barbachyn MR, Hutchinson DK, Manninen PR. Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections. J Med Chem 2008;51:1981-1990. doi: 10.1021/jm800038g; 10.1021/jm800038g
30. Lovering AM, Zhang J, Bannister GC, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002;50:73-77.
31. Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother 2003;47:548-553.
32. Bhalodi AA, Papasavas PK, Tishler DS, Nicolau DP, Kuti JL. Pharma-cokinetics of intravenous linezolid in moderately to morbidly obese adults. Antimicrob Agents Chemother 2012. doi: 10.1128/AAC.01453-12
33. Di Paolo A, Malacarne P, Guidotti E, Danesi R, Del Tacca M. Pharmacological issues of linezolid: an updated critical review. Clin Pharma-cokinet 2010;49:439-447. doi: 10.2165/11319960-000000000-00000
34. Vardakas KZ, Kioumis I, Falagas ME. Association of pharmacokinetic and pharmacodynamic aspects of linezolid with infection outcome. Curr Drug Metab 2009;10:2-12.
35. Thallinger C, Buerger C, Plock N, et al. Effect of severity of sepsis on tissue concentrations of linezolid. J Antimicrob Chemother 2008;61:173-176. doi: 10.1093/jac/dkm431
36. Grohs P, Kitzis MD, Gutmann L. In vitro bactericidal activities of line-zolid in combination with vancomycin, gentamicin, ciprofloxacin, fu-sidic acid, and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:418-420.
37. Jacqueline C, Caillon J, Le Mabecque V, et al. In vitro activity of linezol-id alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother 2003;51:857-864. doi: 10.1093/jac/dkg160
38. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(suppl 2):S27-S72. doi: 10.1086/511159
39. Hannan A, Absar M, Usman M, Naeem T, Saleem S, Arshad M. In vitro activity of linezolid against clinical isolates of methicillin resistant Staphylococcus. J Ayub Med Coll Abbottabad 2009;21:106-109
40. Nannini E, Murray BE, Arias CA. Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol 2010;10:516-521. doi: 10.1016/j.coph.2010.06.006